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ABSTRACT
The purpose of this study was to determine the effect of chromium 
supplementation on the blood glucose control of individuals with type 2 diabetes. A 
positive finding would result in substantial health and financial benefits for individuals 
with this disease. In the previous literature, some studies have found that supplementation 
with chromium improves blood glucose control, while others have reported no effect; 
hence the need for more research. This study utilized a repeated measures, double-blind, 
cross-over design, consisting of two study periods separated by a washout period. Both 
study periods, as well as the wash-out period, were two months in duration. The sample 
used in this study was comprised of 12 individuals (9 men and 3 women). Each study 
period saw half the subjects taking a 400 pg glucose tolerance factor (GTF) chromium 
supplement per day while the other half received a placebo. The dependent variable, or 
primary outcome measure o f blood glucose control, was haemoglobin A le (HbAlc). 
Analysis revealed no evidence of a carry-over effect between periods, so data could 
justifiably be pooled into change scores from pre to post. Analysis o f this data using a 
repeated measure, within-subjects t-test found no significant differences in HbAlc after 
treatment with chromium as compared to the placebo. These findings support those 
previous studies that have found no effect of chromium supplementation on blood 
glucose control.
11











Chapter Two: Review of Literature
2.1 Introduction
2.2 Methods for Reviewing Literature
2.3 Results of Literature Review
2.4 Discussion o f Literature




3.3 Rationale for Procedures
3.4 Data Analysis
Chapter Four: Results
4.1 Test for Carry-over Effect
4.2 Main Analysis
Chapter Five: Discussion




































R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Appendices
A; Characteristics of Studies Reviewed 
B: Article from The Chronicle Journal 
C: Cover Letter 
D: Participant Consent Form
Tables
1: Scoring System Used To Critique Articles 
2: Study Design
3; References Suggesting a Time Frame for HbAlc 
4: HbAlc of Each Subject at Each Test Period 
5; Important Mean HbAlc Levels with Standard Deviations
Figures
1: Mean HbAlc Levels with Standard Deviations
IV
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
CHAPTER 1: INTRODUCTION 
1.1: PURPOSE
The purpose of this study was to determine the effects of chromium 
supplementation on the blood glucose control o f individuals with type 2 diabetes. Blood 
glucose control was measured using haemoglobin A le (HbAlc).
1.2: IMPORTANCE OF STUDY
Diabetes mellitus is a metabolic disorder characterized by the presence of 
hyperglycemia due to defective insulin secretion, insulin action or both. The chronic 
hyperglycemia of diabetes mellitus is associated with significant long-term sequelae, 
particularly damage, dysfunction and failure of various organs -  especially the kidney, 
eye, nerves, heart and blood vessels (Meltzer et al., 1998).
Type 1 diabetes (also commonly inappropriately referred to as insulin-dependent 
diabetes mellitus or IDDM) encompasses diabetes that is primarily a result of pancreatic 
beta-cell destruction and that is prone to ketoacidosis. This form includes cases due to an 
autoimmune process and those for which the etiology of beta-cell destruction is unknown 
(Meltzer et al., 1998).
Type 2 diabetes (also commonly inappropriately called non-insulin-dependent 
diabetes mellitus or NIDDM) may range from predominant insulin resistance with 
relative insulin deficiency to a predominant secretory defect with insulin resistance 
(Meltzer et al., 1998). It is within this disease-state where chromium's role as an insulin 
potentiator (Vincent, 1999) may prove particularly beneficial. If supplemental chromium 
could be used to help insulin-resistant individuals utilize their insulin more efficiently.
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the characteristic hyperglycemia of diabetes mellitus could be lessened or avoided. Some, 
but not all, previous studies have confirmed this speculation.
Currently, approximately 5% of Canadians or 1.5 million people have been 
diagnosed with diabetes mellitus (Tan & McLean, 1995). Although the distinction is 
often unclear, type 2 diabetes may account for 90% to 95% of all cases (Mahan & Escott- 
Stump, 2000). There is no data available as to the exact cost of diabetes treatment in 
Canada, however, data from the United States suggest that diabetes and its management 
consume approximately one in seven health care dollars (Rubin, Altman & Mendelson, 
1994). It stands to reason that an inexpensive mineral supplement, if found to be 
effective, would ease this financial burden.
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1.3: DEFINITIONS
Ataxia -  an inability to coordinate muscle activity during voluntary movement; most 
often due to disorders of the cerebellum or the posterior columns of the spinal cord; may 
involve the limbs, head or trunk (Barlow-Pugh, 2000).
Encephalopathy -  any abnormal condition of the structure or function of brain tissues, 
especially chronic, destructive, or degenerative conditions such as Wernicke's 
encephalopathy or Schilder's disease (Anderson, K.N. & Anderson, L.E., 1998).
Glycosuria -  urinary excretion of carbohydrates (Barlow-Pugh, 2000).
Haemoglobin A le - a haemoglobin A molecule with a glucose group on the N-terminal 
valine amino acid unit of the beta chain. The HbAlc concentration represents the average 
blood glucose level over the previous several weeks (Anderson K.N. & Anderson L.E.,
1998).
Interstitial Nephritis -encompasses a group of clinical disorders that affect principally the 
renal tubules and interstitium, with relative sparing of the glomeruli and renal 
vasculature. Most cases of interstitial nephritis can be classified into one of two types: 
acute causes a rapid decline in renal function, characterized by an acute inflammatory 
infiltrate; chronic causes a progressive deterioration in renal function, characterized by 
interstitial scarring and fibrosis (Andreoli, 2001).
Ketoacidosis -  acidosis accompanied by accumulation of ketones in the body, resulting 
from extensive breakdoAvn of fats because of faulty carbohydrate metabolism. It occurs 
primarily as a complication of diabetes mellitus and is characterized by a fhiity odour of 
acetone on the breath, mental confiision, dyspnea, nausea, vomiting, dehydration, weight 
loss and, if untreated, coma (Anderson, K.N. & Anderson, L.E., 1998).
Peripheral Neuropathy -  any disorder affecting the peripheral nervous system (Barlow- 
Pugh, 2000).
Sequelae -  a condition following as a consequence of a disease (Barlow-Pugh, 2000).
Thrombocytopenia -  reduction in the number of platelets. There may be decreased 
production of platelets, decreased survival o f platelets, and increased consumption of 
platelets or splenomegaly. Thrombocytopenia is the most common cause of bleeding 
disorders (Anderson, K.N. & Anderson, L.E., 1998).
Total Parental Nutrition -  the administration of a nutritionally adequate hypertonic 
solution consisting of glucose, protein hydrolysates, minerals and vitamins through an 
indwelling catheter. The procedure is used in prolonged coma, severe uncontrolled 
malabsorption, extensive bums, gastrointestinal fistulas, and other conditions in which 
feeding by mouth cannot provide adequate amounts of the essential nutrients (Anderson, 
K.N. & Anderson, L.E., 1998).
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
1.4; ABBREVIATIONS
Al = adequate intake 
DNA = deoxyribonucleic acid 
DRI = dietary reference intake 
GTF = glucose tolerance factor
HbAlc = haemoglobin A le (or glycosylated haemoglobin)
IDDM = insulin-dependent diabetes mellitus
NIDDM = non-insulin dependent diabetes mellitus
RD A = recommended dietary allowance
TPN = total parental nutrition
UL = upper limit
pg = microgram
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1.5: LIMITATIONS
Some limitations of the study include the following:
1) Eight week test periods -  Neither the time required for chromium to begin working or 
the period of blood glucose control reflected by HbAlc are known precisely. If  either 
of these time periods is longer than eight weeks, then the length of test periods used 
in this study could be a limitation. However, on both counts, enough evidence was 
found to justify using test periods of eight weeks duration. Also, shorter rather than 
longer test periods were chosen to minimize subject burden.
2) No reliable way to assess chromium status -  As is common with other trace minerals, 
extra chromium will be of no benefit to a person who already has ample stores. 
Although previous research has provided evidence that diabetics excrete more 
chromium than healthy controls (Morris et al., 1999), leading to speculation that they 
may be prone to chromium deficiency, it was impossible to determine the actual 
chromium status of the subjects in this study. Presently, there is no universally 
accepted measure of clinical chromium status (Hellerstein, 1998; Mertz, 1993). What 
this means is that it is not possible to pinpoint whether any beneficial effects of 
chromium would be nutritional or pharmacological in nature. However, regardless of 
the means, any finding of a treatment improving blood glucose control in a sample of 
diabetics would still be important. Until a means of gauging an individual's stores of 
biologically important chromium is found, all chromium researchers will face this 
limitation.
3) Geographically dispersed sample -  Three subjects lived in Dryden, Ontario and 
another who did live in Thunder Bay had no means to get to the Lakehead University
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Campus. Because one third o f the subjects in the study were never seen by the 
researcher, measurements such as body weight, body composition and pill count were 
not taken. In order to monitor body weight changes and compliance to pill-taking, the 
subjects were periodically contacted and questioned regarding these issues. One 
measure known to indicate increased chromium intake is urinary chromium excretion 
(Vincent, 2003). However, budgetary restraints prohibited such a recording from 
being taken.
4) Information on other moderating factors -  Physical activity level was not quantifiably 
recorded. Instead, verbal reports were used as they were for body weight changes and 
pill-taking compliance. Alterations in eating habits may also influence HbAlc, so 
three-day food records may have been helpful in explaining the data. In any case, 
these limitations, as well as body weight monitoring are partly off-set by the cross­
over design used in the study. With such a design, each subject serves as their own 
control, and it is assumed that their lifestyle would not drastically change over the 
duration of the study.
1.6: DELIMITATIONS
This study was delimited to adults (youngest subject was 41) with type 2 diabetes.
The study was further delimited to the effects on HbAlc of a dosage o f400 pg of glucose
tolerance factor (GTF) chromium administered for eight weeks.
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CHAPTER 2: REVIEW OF LITERATURE 
2.1: INTRODUCTION 
Background Information
Chromium's role in nutrition was first elucidated in 1959 with the demonstration 
of the existence of a chromium-dependent dietary factor which was absent in the diets of 
rats fed Torula yeast as their sole protein source. Rats consuming the diet developed an 
inability to remove glucose efficiently fi"om the bloodstream, which was reversed by 
adding foods rich in chromium or by adding synthetic inorganic trivalent chromium. This 
chromium-dependent dietary factor was named “glucose tolerance factor” (GTF) 
(Schwartz & Mertz, 1959).
Conclusive evidence of the role of trivalent chromium in human nutrition was 
first reported in 1977 when symptoms including hyperglycemia, weight loss, ataxia, and 
peripheral neuropathy in a female patient on long-term total parenteral nutrition (TPN) 
were alleviated by supplemental chromium (Jeejeebhoy, Chu, Marliss & Greenberg, 
1977). Similar cases have been documented in the scientific literature several times since 
then (Anderson, R.A. et al., 1997b; Mertz, 1993). Medical studies would appear to 
indicate that chromium is required for normal carbohydrate and lipid metabolism. 
However, beneficial effects fi’om the administration of chromium have not been observed 
in all cases (Vincent, 1999).
The reported beneficial effects of chromium have included potentiation of insulin, 
weight loss, increased burning of fat, muscle gain (Lukaski, 1999), decreased cholesterol 
levels and diabetes control (Hellerstein, 1998). There has even been a study reporting that 
chromium picolinate increases longevity (albeit in a population of rats) (Evans & Meyer,
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1992). Reports such as these have contributed to chromium becoming the second largest 
selling mineral supplement in the United States, behind only calcium (Hellerstein, 1998). 
Chromium supplements (specifically chromium picolinate) generated nearly half a billion 
dollars in sales in 2000 (Mirasol, 2000).
Basic Chromium Biochemistry
Chromium is an essential trace element that can occur in several oxidative states, 
but the two most commonly occurring forms are hexavalent (VI) and trivalent (III) 
(Cerulli, Grabe, Gauthier, Malone & McGoldrick 1998; Jeejeebhoy, 1999). Trivalent 
chromium is the form associated with nutrition, while hexavalent chromium is used 
industrially for dyes, leather tanning and chrome plating (Katz & Salem, 1993).
Therefore, unless otherwise specified, the use of the word “chromium” will refer to 
trivalent chromium for the remainder of this report.
The understanding of chromium's role in nutrition has been hindered by the 
failure to determine the structure, function and mode of action of biologically active 
chromium (which has recently led some to question the need for chromium) (Vincent, 
1999), and by the lack of universally accepted measures of clinical chromium status 
(Hellerstein, 1998; Mertz, 1993) and chromium deficiency (Jeejeebhoy, 1999). These 
limitations will be discussed in detail now.
Progress in the mechanistic understanding of chromium biochemistry has proven 
to be exceedingly difficult (Hellerstein, 1998). Most of today's evidence suggests that the 
GTF is, in fact, not the intrinsic biologically active form of chromium as Schwartz and 
Mertz suggested in 1959. Neither is chromium picolinate the intrinsic biologically active
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form. These chromium complexes are most likely only readily absorbable sources 
(Vincent, 1999).
A breakthrough in establishing the mechanism of chromium action at a molecular 
level occurred in the 1980's when a unique chromium binding oligopeptide was 
identified. This molecule was called low-molecular-weight chromium binding substance 
or chromodulin (Vincent, 2000a). At present, this seems to be the most likely candidate 
for the biologically active form of chromium (Vincent, 1999, 2000b). Several studies on 
rat adipocytes have demonstrated the ability of chromodulin to potentiate the effects of 
insulin on the conversion of glucose into carbon dioxide or lipid (Vincent, 1999, 2000a). 
The stimulation occurs without changing the concentration of insulin and is directly 
dependent on the chromium content of chromodulin (Vincent, 2000a). A study by 
Vincent in 1999 showed that approximately four chromic ions per oligopeptide are 
required for maximal activity, which is consistent with the results of other studies. 
Chromodulin is thought to exist inside insulin-sensitve cells in a chromium-ffee form, 
called apo-chromodulin. Increases in plasma insulin concentrations have been found to 
result in movement of chromium from the blood into insulin dependent cells. This 
transfer is likely mediated by the transport protein transferrin. Once inside the cell, 
chromium binds to apo-chromodulin, which can then bind to the insulin receptor, helping 
to maintain its active conformation and amplifying insulin signalling (Vincent, 1999, 
2000a). In summary, chromodulin's role in glucose metabolism appears to occur after 
insulin binds to its receptor and at or before carbohydrate is transported into the cell 
(Vincent, 1999, 2000b).
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If this mechanism involving chromodulin is correct then several points can be 
rationalized. For one, it can be seen why chromium serves only as a nutrient and not as a 
therapeutic. Benefits of extra chromium would only occur in those people who have less 
than adequate amounts to stimulate all the insulin receptors. Also, if this mechanism is 
correct, then chromium must be removed from cells to stop the activation activity. 
Studies show that urinary chromium losses increase after ingestion of high-carbohydrate 
loads. Presumably, chromodulin may be removed from insulin responsive cells to relieve 
its effects and then excreted in urine (Vincent, 1999, 2000b).
The combination of no measurable physiological or biochemical parameter 
affected by chromium deficiency or repletion and no reliable biochemical index of 
chromium status helps explain both the slow scientific progress and the emergence of 
potentially unfounded health claims regarding this nutrient. Because no intermediate 
physiological markers of chromium adequacy are available, claims about chromium 
deficiency or replacement cannot easily be tested. And because subjects cannot be 
stratified on the basis of baseline chromium status, proper selection or stratification of 
subjects for clinical intervention trials has not been possible (Hellerstein, 1998; Lukaski, 
1999).
At present, there is no solid method to diagnose chromium deficiency. Most 
diagnoses have been made retrospectively in patients on TPN that unexpectedly 
developed hyperglycemia and neuropathy and responded to chromium inftision 
(Jeejeebhoy, 1999; Vincent, 2000a). Elevated levels of plasma chromium while on TPN 
cannot be interpreted as adequate intake, as those patients who have experienced these 
symptoms have had elevated plasma chromium levels (Jeejeebhoy, 1999). Studies have
10
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shown that circulating chromium does not reflect chromium concentrations in 
biologically important tissues (Lukaski, 1999; Mertz, 1993). In general, the symptoms 
reportedly associated with chromium deficiency include impaired glucose tolerance, 
elevated circulating insulin concentration, glycosuria, fasting hyperglycemia, 
hypoglycemia, neuropathy, encephalopathy, increased intraocular pressure, decreased 
insulin binding and decreased insulin receptor number (Jeejeebhoy et al., 1977; Luskaski,
1999).
Chromium and Food
The 1989 edition of the Recommended Dietary Allowances (RDA's) listed an 
estimated safe and adequate daily dietary intake for chromium to be 50-200 pg/day (Food 
and Nutrition Board, 1989). Since that time, a new system known as the Dietary 
Reference Intakes (DRI's) has replaced the RDA's as the main reference for nutrient 
requirements. Under the new DRI system, an adequate intake (Al) for chromium has 
been established at 35 pg/day and 25 pg/day for young men and women, respectively.
The Al for a nutrient is the amount believed to cover the needs of all individuals in the 
group, but lack o f data or uncertainty in the data prevent being able to specify with 
confidence the percentage of persons covered by this intake. For this reason, the Al for 
chromium was set based on estimated mean intakes (National Academic Press, 2002); a 
study by Anderson, R.A. and Kozlovsky (1985) reported mean daily intakes of 33 ± 3 pg 
for men and 25 ± 1 pg for women consuming normal diets.
Even diets designed by nutritionists may be deficient in chromium; in 1992 
Anderson, R.A., Bryden and Polansky analyzed the chromium content of 22 daily diets
11
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designed by nutritionists to be well-balanced. The average amount of chromium per diet 
was only 13.4 ug/1000 Calories.
Chromium naturally occurs in food sources such as Brewer's yeast, animal meats 
and whole grains (Cerulli et al., 1998). In 1992 Anderson, R.A. et al. measured the 
chromium content of various foods and found beef cubes and turkey ham (a luncheon 
meat) to have the highest amount of chromium per serving among the meat products 
measured. Waffles, English muffins and bagels were the highest among grain products, 
while the content of fmits and vegetables varied widely, with juices, green beans and 
broccoli having the most chromium per serving. However, determining the exact amount 
of chromium in a food can prove arduous for a number of reasons. For one, chromium is 
only present in foods in very small amounts (Lukaski, 1999). Also, the content of 
individual lots of the same food can vary widely, and seems to be dependent on 
chromium introduced in the growing, transport, processing and fortification of the food 
(Anderson, R.A. et al., 1992). These factors were only realized in the last twenty years, so 
reports of the chromium content of foods made before this time are often mistakenly high 
(Lukaski, 1999).
In its inorganic state, very little trivalent chromium is absorbed, perhaps less than 
2 percent of the dose (Jeejeebhoy, 1999). Several dietary factors seem to influence 
chromium uptake, although the exact mechanism of absorption is unclear. Oxalate intake, 
iron and zinc deficiency, ascorbic acid, nicotinic acid and diets with less than 40 pg of 
chromium per day have been shown to increase absorption (Anderson & Kozlovsky, 
1985). Phytate intake has been shown to decrease absorption (Jeejeebhoy, 1999). Also, 
consuming a high-sugar diet may contribute to an inadequate chromium intake in two
12
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ways: 1) high-sugar diets are usually low in chromium and 2) high-sugar diets have been 
shown to increase chromium excretion (Anderson, R.A., 1997a). Some non-dietary 
factors causing chromium depletion include certain physiological stressors such as 
physical trauma, acute (but not chronic exercise), lactation (Lukaski, 1999) and aging 
(Jeejeebhoy, 1999).
In contrast, organic forms found in supplements such as chromium nicotinate, 
chromium picolinate and chromium in yeast are better absorbed (Jeejeebhoy, 1999), 
perhaps as much as 4-5% (Vincent, 2003). Some interesting information about the fate of 
absorbed chromium picolinate was discovered in the 2002 in-vivo study by Hepburn and 
Vincent. The researchers injected rats with chromium and H-labeled chromium picolinate 
for 14 days. Injection was used to avoid the low absorption rates that accompany oral 
ingestion. The amount injected daily corresponded to 5 pg of chromium, which after 
accounting for differences in body size, would be equivalent to a slightly greater than 
average amount of chromium ingested normally for humans. They concluded that 
chromium picolinate is degraded rather rapidly in cells (within 24 hours of injection). 
Although the liver and kidney accumulated appreciable amounts of chromium from the 
supplement, the vast majority, if not all o f the chromium was not in the picolinate form 
after 24 hours. While this decomposition minimizes the risk of deleterious effects from 
chromium picolinate itself, it does not eliminate the need for long-term studies.
Toxicity
Chronic exposure to hexavalent chromium has been linked to a variety of health 
problems, including lung cancer, and is 100 times more toxic than trivalent chromium 
(Katz & Salem, 1993). From a dietary perspective, trivalent chromium is considered safe
13
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when consumed in normal amounts (Cerulli et al., 1998; Lukaski, 1999); it is also 
considered to have a safety factor that is much higher than many other trace elements 
(Jeejeebhoy, 1999). So few serious adverse effects have been associated with excess 
intake of chromium from food, a tolerable upper intake level (UL) has not been 
established (National Academic Press, 2002).
From the perspective of chromium supplementation, 19 randomized clinical trials 
in which individuals received between 175 pg and 1000 pg/day of chromium 
supplements orally for durations ranging from 6-64 weeks, produced no evidence of any 
toxic effects (Jeejeebhoy, 1999). In 1997, Anderson, R.A. pointed out that there had been 
no controlled studies documenting any negative effects of chromium supplements taken 
orally in the last 30 years. Despite the lack of toxicity reported in these controlled trials, 
the potential for chromium toxicity would seem to be greater when ingesting 
supplemental, rather than dietary chromium, as the supplemental form is better absorbed 
(Vincent, 2003). There have been at least three cases of chromium toxicity from 
supplementation reported in the literature, all of which involved chromium picolinate. 
These cases are described below:
1) Female, 33 years old who presented to hospital with weight loss (4.5 kg in the 
previous two weeks and 11.4 kg over three months), anemia, thrombocytopenia, 
hemolysis, liver dysftmction and renal failure. She had ingested 1200-2400 pg of 
chromium per day (in the form of 200 pg tablets of chromium picolinate) over 4-5 
months to enhance weight loss. She was subsequently diagnosed with an eating 
disorder. After 26 days of hospitalization, the patient was discharged with a final
14
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diagnosis of hemolysis, as well as acute liver and renal failure secondary to chromium 
toxicity (Cerulli et al., 1998).
2) Female, 49 years old who ingested 600 |ig/day of chromium picolinate for six weeks 
to lose weight. Five months after the ingestion of chromium, the patient presented 
with severe chronic active interstitial nephritis consistent with heavy metal exposure. 
However, the likelihood of this patient's nephritis being attributable to chromium 
toxicity was heavily questioned in a series of letters to the editor subsequent to the 
original article (Wasser, McCarty, Hathcock, Michenfelder & Mennen, 1997).
3) Female, 67 kilogram body builder, 24 years old with no significant medical history 
presented with dehydration and a four day history of diffuse muscle weakness, pain 
and bilateral leg cramping. Two days before the onset of the cramping, she added 
chromium picolinate to her complex dietary supplement regime. She consumed 1200 
pg of chromium over 48 hours. The diagnosis was rhabdomyolysis. Although the 
patient was a well-conditioned athlete who had maintained a stable diet and exercise 
program for eight weeks before taking chromium picolinate and developing the 
syndrome, the authors do admit that considering the multitude of supplements she 
was consuming and the fact that she was involved in strenuous exercise, it was 
impossible to exclude other etiologies (Martin & Fuller, 1998).
Other potentially worrisome results have been found in in-vitro studies. As with 
the case studies, all in-vitro studies reporting deleterious effects used the chromium 
picolinate form. Perhaps the most famous of these was the study by Steams, Wise, 
Patierao and Wetterhahn in 1995, which tested several trivalent chromium complexes for 
their ability to produce chromosomal aberrations (clastogenicity) in Chinese hamster
15
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ovary cells. This study concluded that chromium picolinate was clastogenic, but the 
clastogenicity was more likely attributable to the picolinate, rather than the chromium. 
Neither chromium chloride nor chromium nicotinate produced such clastogenic damage. 
However, Lukaski (1999) noted that the concentration of chromium picolinate added to 
the cell culture system exceeded by more than 1000 times the concentration of chromium 
reported in human circulation. Therefore, the results of this experiment may not be 
applicable to human models.
Another study in 1999 by Speetjens, Collins, Vincent and Woski using 
concentrations of chromium picolinate believed to correspond to those in the cells of 
individuals taking the supplement for prolonged periods of time found that significant 
DNA cleavage resulted from the generated hydroxyl radicals. The damage was likely 
attributable to the combination of chromic ions and picolinate, which yields an alteration 
in the redox potential of chromium making it susceptible to biologically relevant reducing 
agents. Neither chromium nor picolinate caused such damage separately.
With such evidence, the potentially harmful effects from supplementation with 
chromium picolinate outweigh the potential benefits, especially when alternative forms of 
chromium supplements are available (Vincent, 2003).
Chromium and Diabetes
Individuals with diabetes have altered chromium metabolism, compared with 
nondiabetic control subjects, with higher chromium absorption but also greater chromium 
excretion. For this reason, it is postulated that the chromium requirement increases with 
increased glucose intolerance in diabetics (Anderson et al., 1997b).
16
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A study with results supporting this postulation was done in 1999 by Morris, et al. 
who assessed chromium handling in 93 type 2 diabetics compared to 33 healthy 
volunteers. Diabetic patients had mean levels of plasma chromium significantly lower 
and urinary chromium values significantly higher than those found in healthy controls. 
Also, the healthy control group showed a significant negative correlation between fasting 
levels of plasma chromium and insulin. This was not evident in diabetic patients. Morris 
et al. concluded that large chromium losses over many years may exacerbate an already 
compromised chromium status in diabetic patients and might contribute to the developing 
of insulin resistance seen in patients with type 2 diabetes.
On a similar note, it has also been postulated that marginal chromium deficiency 
may increase an individual's risk for developing diabetes (Mertz, 1993).
2.2: METHODS FOR REVIEWING LITERATURE
A PubMed search was performed in October o f2001 using the words 
“chromium” and “diabetes”. The search was limited to articles dealing only with human 
models, written in English and dating back to 1966. This search yielded 201 references of 
which the abstracts were scanned. All available articles deemed relevant were reviewed. 
Any articles dealing with chromium as it pertains to diabetes in children or pregnant 
women were not reviewed. Also, articles must have had some measure of blood glucose 
control as a dependent variable to qualify for review. Further references were obtained by 
accessing other databases, namely: Cumulative Index to Nursing and Allied Health 
Literature, Sport Discus. Finally, other relevant articles cited in the reference lists of the 
articles found using these database searches were reviewed. A second PubMed search 
was conducted in June of 2003.
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Of the articles reviewed, 22 were original experiments; a summary o f their results 
is presented in Appendix A. Each of these studies underwent a quality critique using a 
scoring system that was designed for this purpose. A summary o f the scoring system can 
be seen in Table 1:
Table 1: Scoring System Used To Critique Articles
Criteria Point Allocation
Compliance testing Compliance tested = 1, no compliance testing = 0
Control Use of a control group = 3, no control = 0
Cross-over design Cross-over + washout = 3, cross-over no washout = 1.5, not a cross-over 
design = 0
Dependent variable HbAlc = 3, other measure of blood glucose = 1.5
Duration 12 or more weeks = 3,8-11 weeks = 2,4-7 weeks = 1, <4 weeks = 0
Statistical analysis Aj^oi»iate = 3, partially appropriate = 1.5, inai^opriate or incomplete = 0
Researcher blinded Proof of blinding = 3, statement of blinding = 1.5, not blind = 0
Subjects blinded Proof of blinding = 3, statement of bUnding = 1.5, not blind = 0
Subject number >30 subjects = 3, 20-29 subjects = 2,10-19 subjects = 1, <10 subjects = 0
Miscellaneous Factors Any other notable characteristics considered for a score out of 1
2.3: RESULTS OF LITERATURE REVIEW
The validity o f pooling the results of all the studies done on the effects of 
chromium supplementation on blood glucose control is compromised by the differences 
in the individual studies. For example, the dosage of chromium supplementation in the 
studies ranged from 10.8 pg to 1000 pg per day. The duration of the test periods ranged 
from 3 weeks to 16 months. Ten studies used chromium in the form of chromium 
chloride, four used chromium picolinate, five used trivalent chromium, six used 
chromium-rich yeast and one study used chromium nicotinate (four studies used more 
than one type). However, by subjecting the studies to the same scoring system, some 
objectivity in evaluating the quality of each study is obtained. Scores of the studies 
ranged from 3 to 21.5, with a mean score of 15.43.
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Of all the different variables, none seemed to be more significant than the diabetic 
status of the subjects. No other variable influenced the effect of chromium 
supplementation on blood glucose control more than this one. For this reason, it was most 
practical to group studies according to this variable and discuss the results of each group. 
Studies on Individuals with Diabetes
Nine of the studies tested diabetic subjects exclusively. Six of these nine reported 
some improvement in blood glucose control after supplementation, while three studies 
reported no improvement. According to the scoring system, the six studies showing 
improved blood glucose control had a total score of 78.5 points. The three studies 
showing no improvement had a total score of 46.5. These scores seem to indicate the 
strength of evidence lies with the studies reporting positive effects o f chromium 
supplementation on blood glucose control in diabetics.
Studies on Individuals without Diabetes
The studies on individuals without diabetes provided the most confusing results 
when pooled. There were nine such studies in total and their results differed widely. Only 
four of the nine studies presented results that could easily be classified into either an 
effect or no effect category.
The double-blind, cross-over study by Anderson, R.A., Polansky, Bryden, 
Bhathena and Canary in 1987 could be said to have found a positive effect. This study 
reported that all measured parameters of blood glucose improved after three months of 
supplementing with 200 pg of chromium chloride. It is interesting to note that all eight 
subjects used in this study had symptoms of hypoglycaemia prior to the initiation of the
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study, suggesting that although not diabetic, their management of blood glucose was 
somewhat impaired.
The study by Wang, Fox, Stoecker, Menendez and Chan (1989) could be 
immediately classified as not showing any significant effect of chromium 
supplementation on blood glucose control. The subjects (who had high serum cholesterol 
at the outset of the study) did however, experience improvements in their cholesterol 
levels. The study by Uusitupa et al. (1992) could be grouped in this same category. This 
study found no differences in any measure of blood glucose between a group receiving 
160 pg of chromium per day and another group receiving a placebo. It is noteworthy that 
the subjects in this study had persistent impaired glucose intolerance. Finally, the study 
by Hermann, Arquitt and Stoecker (1994) reported that fasting blood glucose was 
unaffected by supplementation, but beneficial effects could be seen in blood lipids when 
subjects were sub-divided according to baseline levels.
The five remaining studies have results that cannot be conveniently summarized 
as having an effect or no effect. Three of these five found differing results for different 
groups within the study. A double-blind, cross-over study by Anderson, R.A. et al. (1983) 
reported no significant effects on fasting blood glucose when all subjects were combined, 
but when subjects were stratified based on the results of a 90 minute glucose tolerance 
test, improvements were seen in blood glucose control in the group with the least amount 
of glucose tolerance. Martinez, MacDonald, Gibson and Bourn (1985) found no effect of 
supplementation in a group of women who took medications that may affect glucose 
tolerance. However, non-medicated subjects who were judged to be at high risk for 
glucose intolerance had a significant decrease in blood glucose two hours post-load. The
20
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
study by Anderson, R.A., Polansky, Bryden and Canary (1991) found that glucose 
tolerance, circulating insulin and glucagon improved only in those subjects who had 
elevated blood glucose levels after a tolerance test performed at baseline.
The last two studies on non-diabetic subjects cannot be easily categorized because 
they found different effects on different measures of blood glucose. Riales and Albrink 
(1981) measured a variety of blood glucose related parameters, but found only fasting 
blood glucose was lowered by chromium supplementation. The study by Urberg and 
Zemel (1987) reported fasting glucose and glucose tolerance after a test were improved 
only by chromium nicotinate, and not by either chromium or nicotinic acid alone. Fasting 
and 1-hour insulin levels or HbAlc were not affected by any treatment.
In summary, although these nine studies did not use diabetic subjects, five of 
them reported at least some of their subjects as having some degree of impaired glucose 
tolerance. Of these five studies, four reported a beneficial effect of chromium 
supplementation while only one reported no effect.
Studies Involving Both Groups of People
Four studies reviewed used a mixture of diabetic and non-diabetic subjects. 
Sherman, Glennon, Brech, Klomberg and Gordon (1968) found chromium 
supplementation to have no effect on fasting or 2-hour post-prandial blood glucose in 
four healthy and 10 diabetic males. Likewise, Abraham, Brooks and Eylath (1992) found 
no effect on blood glucose when comparing groups receiving either 250 pg of chromium 
chloride per day or a placebo; however, beneficial changes were seen in some blood 
lipids.
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Contrary to these findings, OfFenbacher and Pi-Sunyer(1980) reported that after a 
glucose load, glucose tolerance improved significantly and insulin output decreased in 16 
healthy and eight mildly diabetic subjects with only 10.8 pg of chromium per day 
compared to a placebo. Glinsmann and Mertz (1966) also concluded that their diabetic 
subjects did improve their blood glucose control over what they described as “long-term” 
supplementation with chromium. No improvements were found with “short-term” 
supplementation in diabetics or with any of their healthy subjects.
2.4; DISCUSSION OF LITERATURE
Upon examining each of these 22 studies at face value, it is difficult to notice any 
trends. Indeed, it is easy to see why such great polarity o f opinions exists regarding the 
benefits of chromium supplementation. However, when the evidence is viewed 
considering the diabetic state of the subjects studied, some degree of clarity is provided. 
Of the 22 studies, 18 used at least some subjects with some degree of impaired blood 
glucose control. Twelve of these 18 studies reported that such individuals improved their 
blood glucose control Avith chromium supplementation. These studies accumulated 174.5 
points. The six studies reporting no effect of supplementation on such individuals 
garnered only 96 points. None of the 22 studies reported negative effects on glucose 
control or any toxic effects in general.
The conclusion of this review is consistent with the conclusions of other reviews. 
Notably, Lukaski (1999), who found that most recent studies on the effects of chromium 
picolinate, or other chromium supplements, on healthy human subjects produced no 
observed beneficial effects from supplementation. Lukaski offered the explanation that 
this was because the subjects in the studies were not chromium deficient. This review
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also supports the argument put forth by Mertz (1993), that an impaired glucose tolerance 
can be improved or normalized by chromium supplementation or can be maintained in 
spite of a reduced insulin output, but a normal glucose tolerance is not further improved. 
The meta-analysis done by Althuis, Jordan, Ludington and Wittes (2002), using data 
from 15 trials and including 618 participants (193 of which had type 2 diabetes), found 
no effect o f chromium supplementation on glucose or insulin response in non-diabetic 
subjects. The effects of chromium supplementation on individuals with diabetes were 
deemed inconclusive, as a result of too few trials with diabetic subjects having been 
conducted.
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2.5; CONCLUSIONS FROM LITERATURE REVIEW
1) Individuals with impaired glucose metabolism may experience improvements in their 
blood glucose control with supplemental chromium. This finding is especially important 
for individuals with diabetes mellitus.
2) Individuals with probable low chromium status may experience decreased blood 
glucose control, which may be alleviated by supplemental chromium. Again, this 
conclusion is particularly important for individuals with diabetes as they tend to excrete 
more chromium, which may exacerbate already compromised blood glucose control
3) A reliable measure of chromium status is sorely needed to stratify patients, compare 
populations, determine deficiency, evaluate compliance, and differentiate between 
replacement and pharmacological effects
4) More understanding is needed with regards to the mechanistic metabolic actions of 
chromium to lower blood glucose concentrations.
5) More studies are needed on the effects of chromium supplementation on blood glucose 
control, particularly in individuals with diabetes
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CHAPTERS; METHODS 
3.1: SUBJECTS
The sample used in this study was comprised of 12 individuals with type 2 
diabetes. Two additional individuals started the study but were unable to finish after 
missed blood tests. The sample consisted of nine men and three women. Nine individuals 
resided in Thunder Bay and three lived in Dry den. The ages of the subjects ranged from 
41 to 74, with a mean age of 59.7. The mean HbAlc level at the onset of the study was
0.07645.
Power analysis revealed that 15 subjects would be needed for the study. This is 
considering that this study used a cross-over design (see Section 3.2) and each subject 
would represent both the placebo and chromium test periods. This was the number of 
subjects calculated to achieve statistical significance with p = 0.05, statistical power equal 
to 90%, an estimated standard deviation of 1.0 and an ability to detect a difference 
between treatment groups in HbAlc of 0.5 (Kraemer et al., 1987).
All subjects were recruited via an article in the October 11* 2002 edition of the 
Chronicle Journal newspaper (see Appendix B). In light of the relative difficulty in 
recruiting subjects, a somewhat liberal inclusion criteria was implemented in this study;
1. Subjects must have been diagnosed with type 2 diabetes mellitus. (This criteria was 
chosen in lieu of a more stringent HbAlc cut-off point in an effort to maximize the 
number of subjects able to participate in the study).
2. Subjects must have been adults
3. Subjects must not have taken chromium supplements two months or less prior to the 
study
4. Subjects must have taken their pill daily (either chromium or placebo)
5. Subjects must have reported to all four testing sessions
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All subjects were informed of the purpose, details and risks of the study and were 
aware that they could withdraw from the study at any time. Approval for the study was 
granted by the Lakehead University Ethics Board.
3.2: PROCEDURES
The study utilized a repeated measures, double-blind, cross-over design, 
consisting of two study periods separated by a washout period. Both study periods, as 
well as the wash-out period, were eight weeks in duration. In each study period, half the 
subjects took a 400 pg glucose tolerance factor (GTF) chromium supplement per day 
while the other half ingested a placebo. Both chromium supplements and placebos were 
supplied by Jamieson's Laboratories and were identical in appearance and taste. Subjects 
were assigned to either group 1 or 2 prior to the beginning of the study in a random draw 
done by an independent party. Testing occurred at the beginning and end of each study 
period, for a total of four separate testing sessions. A table outlining the study design is 
presented below;
Table 2: Study Design
Test 1 Test 2 Test 3 Test 4
Group 1 (n=6) Chromium Wash-out Placebo
Group 2 (n=6) Placebo Chromium
WeekO Week 8 Week 16 Week 24
The dependent variable, or primary outcome measure of blood glucose control, 
was haemoglobin A le (HbAlc). Each subject reported to their most conveniently located 
MDS Laboratory for the blood drawing. MDS Labs also handled the HbAlc analysis 
from the blood samples. Regular telephone interviews were conducted with subjects to 
monitor pill-taking compliance, and body weight and physical activity changes.
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3.3: RATIONALE FOR PROCEDURES
Why Use HbAlc as the Measure of Blood Glucose Control?
The Diabetes Control and Complications Trial (DCCT) showed conclusively that 
glycemic control as assessed by HbAlc can predict the risk of developing microvascular 
diabetic complications in type 1 patients (DCCT Research Group, 1993). This finding 
was later expanded to include type 2 diabetics with The United Kingdom Prospective 
Diabetes Study (the largest clinical study of diabetes ever attempted, conducted over 20 
years and involving 5,102 type 2 diabetics) (U.K. Prospective Diabetes Study Group, 
1998). As a consequence, the usefulness of the HbAlc assay has been validated and its 
use recommended (Kilpatrick, 1997). It is currently the pre-eminent measure of long­
term blood glucose control reported in biomedical literature (Austin, 2001; Hom, Ettinger 
& Lin, 1998).
Why a Cross-Over Design?
The advantages of a cross-over design are well known. Comparisons of treatments 
are made within-subjects, predisposing them to within-subject, rather than between- 
subject error (Armitage & Hills, 1982). This design affords the use of statistical tests with 
greater power; that is, a difference of a given size between two sample means is more 
likely to be found significant using a within-subjects test than a between-subjects test 
(Diekhoff, 1992). Another advantage is that since more precision is obtained with this 
method, the number of subjects needed for the experiment is economized (Armitage & 
Hills, 1982).
Another reason for implementing a cross-over design is that previous studies on 
chromium and blood glucose control have either not done so, or failed to do so
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effectively. Of the 22 prior studies on this topic, eight employed the cross-over technique; 
however, four of these studies had no wash-out period between trials and two other 
studies had wash-out periods of less than two weeks. Failure to include a wash-out 
period, or wash-out periods o f such a short duration compromise the findings of these 
studies. Only one study to date has had a wash-out period of a similar length to the one 
used in this investigation (eight weeks). The eighth study gave no indication if a wash-out 
period was used or not.
Why Eight Weeks Duration for Each Study Period and Wash-Out?
Choosing the duration of the study periods was dependent largely on the 
physiology of the main dependent variable, HbAlc. Two months seems to be a 
reasonable estimate as to the time period over which HbAlc reflects blood glucose 
control. Although there does not seem to be a consensus as to exactly how long a period 
of blood glucose control HbAlc reflects, several sources have indicated that two months 
is a reasonable estimation. References citing time frames over which HbAlc reflects 
blood glucose control are presented in the following table;
Table 3: References Suggesting a Time Frame for HbAlc
Author and Year Suggested Range
Austin, 2001 2-3 months
Mahan & Escott-Stump, 2000 2-3 months
Hom et al., 1998 2-3 months
Meltzer et al., 1998 2-4 months
Kilpatrick, 1997 6-8 weeks
Tahara & Shima, 1995 1-3 months
Goldstein et al., 1994 2-3 months
Koch, 1990 2-3 months
One of the previous cross-over studies used two-month test periods, three used 
shorter test periods and four used longer test periods. Selecting a longer test period would
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increase subject burden, and is not necessarily justified considering the physiology of 
HbAlc.
Why Give 400 jig of Chromium?
Firstly, evidence that 400 pg is an acceptable dose can be found in the previous 
22 studies on chromium supplements and blood glucose control. The most common 
dosage used in these studies has been 200 pg per day, which was used in nine studies. 
Two studies have used the same dose as that used in this study, 400 pg. Three studies 
have used doses higher than this; two have used 600 pg and one study used as much as 
1000 pg. None of these studies documented any negative effects of their chromium 
supplements. Essentially, and most importantly, negative side effects resulting from 
ingestion of this amount of chromium was highly unlikely.
Secondly, chromium has an established safety factor that is much higher than 
many other trace elements (Jeejeebhoy, 1999). For dietary chromium, the intake at which 
harmful or toxic effects result is so high that it currently can only be estimated (Vincent, 
2003).
Thirdly, higher doses may be particularly well tolerated by people with diabetes, 
as were used in this study. There is evidence to suggest that diabetics have greater than 
normal chromium excretion, therefore, a greater than normal chromium requirement 
(Anderson, R.A. et al., 1997b; Morris et al., 1999). Admittedly, the established adequate 
intake (Al) for chromium cannot specify with confidence the percentage of persons 
covered by this intake (National Academic Press, 2002). It is likely that the persons with 
diabetes require a chromium intake greater than the AX.
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Finally, 400 jxg was selected over a lower dose to try and avoid a “no effect” 
result simply because subjects did not receive enough chromium.
What Type of Chromiuin Supplement Will Be Used?
This study used tablets containing GTF chromium. There were two main 
advantages of using this type of chromium:
1) No study to date has used a GTF chromium supplement. Perhaps the most similar 
chromium supplement is chromium nicotinate. Nicotinic acid has been identified as 
possibly, but not conclusively, being part of the GTF complex (Mahan & Escott-Stump, 
2000). Only one previous study has used chromium nicotinate in examining effects on 
blood glucose control (Urberg & Zemel, 1987). In summary, more research is needed on 
this form of chromium supplement.
2) In-vitro studies suggest that forms of chromium other than picolinate are unlikely to be 
susceptible to generating the same type of oxidative damage; therefore, the use of 
compounds other than chromium picolinate would appear warranted (Vincent, 2003).
3.4; DATA ANALYSIS
The intent when using a cross-over design is to ultimately pool the data obtained 
from both test periods. However, this step is not always justifiable. It must first be 
determined if there is a treatment X period interaction, otherwise known as a carry-over 
effect. Only after such an effect is disclaimed can the data be pooled (Armitage & Hills, 
1982).
Two methods outlined by Hills and Armitage (1979) were used to test for this 
treatment X period interaction:
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1) An independent t-test between the HbAlc change scores of groups 1 and 2 after each 
of their respective chromium supplementation periods (for group 1, the change scores 
for weeks 0-8; and the change scores from weeks 16-24 for group 2). Another 
independent t-test was run comparing the HbAlc change scores for both groups' 
placebo periods.
2) A dependent sample t-test between each subject's HbAlc level before each test 
period i.e. test 1 and test 3. This was to ensure that each subject's HbAlc level was 
relatively similar before the start of both test periods.
Upon discovery that these procedures both produced no significant differences 
(^>.05), it could safely be assumed that the washout-period was effective and data from 
the two test periods could be pooled into change scores for the main analysis; basically, 
leaving each subject with two pieces of data for comparison: 1) the difference between 
their HbAlc level pre and post chromium supplementation period and 2) the difference 
between their HBAlc level pre and post placebo. Data such as this lends itself to 
statistical analysis using a repeated measure, within-subjects t-test. With this procedure, it 
was possible to determine the significance of the effect of chromium supplementation on 
HbAlc in comparison to the placebo.
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CHAPTER FOUR: RESULTS
4.1; TEST FOR CARRY-OVER EFFECT
The independent t-tests produced values of t(io> = -1.337 and 0.541 for the tests in 
HbAlc difference pre and post chromium and placebo, respectively. Neither value 
exceeded the t(cnt)= 2.228 at a significance level ofp =.05 and were therefore not 
significant. The dependent t-test on the HbAlc levels of all individuals at test 1 and test 3 
produced a result of t(H) = 0.217 < t(crit) = 2.201, again indicating a non-significant 
difference. Since no procedure used to test for a treatment X period effect produced a 
significant result, a carry-over effect was not present. Therefore, data from the two test 
periods could be pooled for the main analysis.
4.2: MAIN ANALYSIS
No subject reported a notable change in their weight throughout the duration of 
the study. One subject reported an increase in exercise during the washout period. 
Individual Raw Data
Table 4: IbA lc of Each Su )ject at Each Test Period
Subject Test 1 Test 2 Test 3 Test 4
(Week 0) (Week 8) (Week 16) (Week 24)
A ‘...... 0.079 0.080 0.071 0.080
B ' 0.055 0.054 0.055 0.058
0.056 0.055 0.054 0.055
D ^ 0.117 0.124 0.096 0.095
E ' 0.080 0.086 0.087 0.083
0.067 0.079 0.057 0.064
0.100 0.102 0.082 0.077
H^ 0.073 0.089 0.095 0.093
0:064 0.065 0.067 0.073
0.075 0.081 0.080 0.081
0.061 0.066 0.066 0.067
0.090 0.086 0.098 0.100
' = subject took Cr during 2"** test period (weeks 16-24)
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Descriptive Statistics
The following table displays the mean HbAlc levels for each group at each 
individual test, as well as the change scores after both the chromium and placebo test 
periods:
Table 5: Im portant Mean HbAlc .̂evels with Standard Devial ions
Group Test 1 Test 2 Change Score 
Weeks 0-8
Test 3 Test 4 Change Score 
Weeks 16-24
1 (n=6)





























Cr = chromium test period; PI = placebo test period
The average HbAlc values along with the standard deviations for both groups at 
each test are illustrated by the following graph:
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In both test periods, mean HbAlc levels increased from pre to post. An 
improvement in blood glucose control would be indicated by a decrease in HbAlc. 
Therefore, before doing any further statistical tests, it is already known that the 
hypothesis of chromium supplements improving blood glucose control will be rejected. 
Dependent t-Test
The mean change score for the 12 subjects during their chromium treatment 
period was -0.0023 (standard deviation 0.0047) compared to a mean change score of 
-0.0034 (standard deviation 0.0057) during the placebo period. The result of the repeated 
measure, within-subjects t-test was t(l 1) = 0.496 < t(crit) = 2.201. Therefore, the 
difference between these two means was not significant. In other words, chromium and 
the placebo did not affect HbAlc differently.
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CHAPTER FIVE; DISCUSSION
The main result o f this study is that chromium supplementation does not improve 
the blood glucose control o f individuals with type 2 diabetes. This finding supports those 
of six previous studies that have explored this topic on individuals with impaired glucose 
metabolism (see Appendix A).
The results of a study such as this have particular interest to the millions of people 
suffering fi'om diabetes around the world, as well as to the various manufacturers in the 
multi-million dollar nutritional supplement industry. However, it is important not to 
extend the findings of this study beyond its previously mentioned delimitations (see 
Section 1.6). This study was delimited to the effects of an eight week daily dose of 400 
pg of GTF chromium on the HbAlc levels of type 2 diabetics who entered the study with 
a mean HbAlc level o f 0.07645. Some of these delimitations will now be discussed in 
further detail, with specific comparisons made to the previous literature when 
appropriate.
5.1: EIGHT WEEK STUDY PERIODS
After conducting the main analysis o f the data, it is clear that the results of this 
study suggest chromium does not improve blood glucose control. However, upon giving 
the data some closer inspection, an interesting pattern is uncovered. Consider the mean 
HbAlc for group 1 at test 1 and test 3 (see Figure 1). At test 1 they had an average 
HbAlc of 0.0757, and by test 3 (after taking chromium for eight weeks, then stopping for 
eight weeks) their average HbAlc had lowered to 0.0700. Although this decrease was not 
deemed statistically significant using a repeated measure, within-subject t-test, such 
improvement in blood glucose control may have some clinical importance. From The
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United Kingdom Prospective Diabetes Study, epidemiological analysis showed that for 
every percentage point decrease in HbAlc (e.g. 9% to 8%) there was a 35% reduction in 
microvascular complications, 25% reduction in diabetes-related deaths, 7% reduction in 
all-cause mortality and 18% reduction in combined fatal and non-fatal myocardial 
infractions. There was also no evidence of any glycemic threshold for any of the 
microvascular or cardiovascular complications above HbAlc levels of 6.2% (U.K. 
Prospective Diabetes Study Gfroup, 1998). Four of the six individuals in group 1 
experienced improvements in their blood glucose control from test 1 to test 3. Subject A 
improved by 0.8%, subject C by 0.2%, subject D by 2.1% and subject F by 1%. The 
HbAlc of subject B remained the same at 0.055 at test 1 and test 3.
Further evidence for the importance of an HbAlc improvement from 0.0757 to 
0.0700 can be found in the 1998 clinical practice guidelines for the management of 
diabetes in Canada. This reference lists values less than 0.070 as an “optimal” level of 
blood glucose control for adults with diabetes. They define “optimal” control as being 
likely related to minimal long-term complications. Contrarily, the subjects' mean HbAlc 
level of 0.757 at test 1 would be classified as “sub-optimal” control under these 
guidelines, or likely not adequate to prevent complications (Meltzer, et al., 1998).
From the group 1 decrease in HbAlc from test 1 to test 3, two theories emerge:
1) It is possible that the chromium took the entire 16 weeks to start working. Since many 
aspects of chromium metabolism remain unknown (Vincent, 1999), the exact time frame 
required for chromium to be assimilated into the bodies' biologically active stores cannot 
be predicted with any certainty.
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2) HbAlc may take longer than eight weeks to reflect changes in blood glucose control. 
Although this time frame does fall into the range suggested by several sources (see 
Table 3), it is at the lower end of most. Choosing a time frame at the higher end o f these 
suggested ranges may have been more appropriate for use in this study. Also, it would 
have been interesting to measure other parameters of blood glucose control at various 
times throughout the study, while still relying on HbAlc as the primary measure of long­
term control.
In the previous literature, there is a precedent for a “no-effect” result in studies 
that have used test periods with durations similar to that of the present study. Uusitupa et 
al. (1983) reported that chromium supplementation had no effect on HbAlc after a 
slightly shorter test period (six weeks) than the one used in this study. Another similarity 
between this and the present study was that both implemented a cross-over design 
(although Uusitupa et al. failed to include a wash-out period). Trow et al. (2000) also 
concluded that chromium failed to improve blood glucose control or insulin levels after 
an eight week supplementation period.
In summary, this study as well as those mentioned above showed no significant 
improvement in HbAlc after eight weeks of supplementation with chromium; therefore, 
we must conclude that individuals with impaired glucose metabolism should not expect 
to find benefits in taking chromium for this length of time. However, after closer scrutiny 
of the data obtained in this study, we may be justified in speculating that benefits may 
occur with longer supplementation.
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5.2: GTF CHROMIUM
This was the first documented study to use GTF chromium. The one study that 
used a similar chromium supplement (chromium nicotinate) also reported a failure of the 
supplement to significantly affect HbAlc (Urberg & Zemel, 1987). It could simply be 
that this type of chromium supplement is not as effective as others.
5.3: HAEMOGLOBIN Ale
Great improvements in HbAlc should not be expected if levels are already fairly 
well controlled. It could be argued that this was the case for the subjects in this study. At 
test 1 the 12 subjects had an average HbAlc of 0.07645. The 1998 clinical practice 
guidelines for the management of diabetes in Canada would classify this level of blood 
glucose control as “sub-optimal”, but not “inadequate”. “Inadequate” control is defined 
by HbAlc levels above 0.084. Such high levels are related to a markedly increased risk 
of long term complications, requiring a reassessment and readjustment of therapy 
(Meltzer et al., 1998). Only three subjects had levels in this range at the onset of the 
study. Only one of these was assigned to receive chromium in the first test period. When 
we use this individual to revisit the postulation that longer study periods may have 
produced more benefits, we see that this subject's HbAlc dropped from 0.117 at test 1 to 
0.096 at test 3, which was the biggest fluctuation of any subject in the study. Four 
subjects fell into the “sub-optimal” category (0.07-0.084), three into the “optimal” 
category (less than 0.07) and two subjects began the study with HbAlc levels that would 
be defined as “ideal” or normal for a non-diabetic individual (0.04-0.06). Both these 
individuals were assigned to group 1. One experienced a 0.2% improvement in HbAlc 
from test I to test 3 (subject C), while the other maintained exactly the same HbAlc level
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at these tests (subject B). Only small improvements in HbAlc levels as low as these 
could be expected, regardless of duration of supplementation. Significant improvements 
as a result of chromium supplementation, or any other treatment, would be more likely to 
be seen in subjects with “inadequate” blood glucose control.
Two examples of similar phenomenon can be pulled from the literature:
Anderson, R.A. et al. (1997b) found chromium to significantly improve HbAlc after two 
months in subjects with initial HbAlc levels ranging from 0.080-0.120. Meanwhile, the 
study by Uusitupa et al. (1992) reported HbAlc remained unchanged by chromium 
supplementation in a sample of individuals who began the study with a mean HbAlc 
level of 0.0535.
5.4: SUMMARY
The main result of this study is that supplementation with GTF chromium was 
unable to significantly improve the HbAlc of type 2 diabetics with a mean initial HbAlc 
level of 0.07645 after an eight week treatment period. Support for this finding can be 
found in the previous literature. The findings of this study should not be generalized 
beyond the specified delimitations. There is room for fiirther study in this area.
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CHAPTER SIX; RECOMMENDATIONS
Future research in the field should heed the following recommendations:
■ Studies should continue to use HbAlc as the measure of long-term blood glucose 
control, however, the duration of the test periods should exceed eight weeks. Test 
periods of 12 weeks or even 16 weeks may be appropriate. For a 16 week test period, 
it may be desirable to do two HbAlc tests, one after eight weeks and another at the 
end of the 16 weeks. If test periods of this length are not possible, post-study follow- 
up tests could be implemented. To conclusively determine the time frame over which 
HbAlc reflects blood glucose control, more research could be done on this topic as 
well.
■ GTF chromium is an under-studied form of this supplement; more research is needed.
■ All studies should report the initial HbAlc levels of the subjects. This will enable 
researchers to test the theory that chromium's ability to improve blood glucose 
control is greater when baseline levels of blood glucose control are inadequate.
■ Obtaining data on other factors that could possibly affect blood glucose control (such 
as body weight, exercise level and diet) can help to better explain the main findings of 
the study.
■ A reliable measure of chromium status is sorely needed to stratify patients, compare 
populations, determine deficiency, evaluate compliance, and differentiate between 
replacement and pharmacological effects.
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Table 6: Studies Using at Least Some Subjects with Some Measure of Impaired Glucose 
Tolerance
Studies Showing Positive Effects on Subjects with Impaired Glucose Tolerance
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Table 6 continued
Studies Showing No Effect on Subjects with Impaired Glucose Tolerance
Sherman et al., 
1968
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yrs = age in years; mos. = months; wks = weeks; d = 
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day; hr = hour; Cr = chromium; 
test
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Table 7: Studies Using Healthy Subjects with Normal Blood Glucose Control
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yrs = age in years; mos. = months; wks = weeks; d = 
CrCl = chromium chloride; GTT = glucose tolerance
day; hr = hour; Cr = chromium; 
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M£October l l ,  2002 h)--*•
SANDI )<RASOWSKI/THE CHRONICl
|}ems Collier is workmg on a siiidy Ijato
X
7|<akeli"ead Uaiversit^ studei 
’thromium supplement̂ . "
Chromium seeh^as 
$o curbiiig tyjie n  di
BY KRIS KETONEN
THE CHRONICIE-JOURNAL____________
' A Lakehead University student is em­
barking on a research project that could 
have positive effects for most diabetes 
sufferers.
Kinesiology master’s student Denis 
Collier is studying the effects of chromi­
um supplements on type n diabetes> cit­
ing previous studies that hint the miner­
al helps the body’s ability to make use pf 
the insulin it produces.
“It’s not all of them (the studies), so 
this is whyjjnpre research is needed,
helps, it will have positive effects^n 
those with type n, he said. '
“If.we can find a way to help^them 
control their blood sugar, obviously big 
unplications for the health pf these peo­
ple,’’he said. i-«:
Collier said it’s Relieved chromium 
helps by attaching tp insulin receptors 
■ in the body’s ceUs,*hhd putting piit a 
“stronger signalto get insulin to attach.” 
The second positive effect would be fi- 
nancial i .
“If we can keep them healthy for a 
longer period of (imerit cptts down, oh 
the cost of healm carei” CoUier said.
Collier said y êaterday at I^ehead tjhi- adding bver-the-cppnter chfoirtiiHh $Up-
versity. ■   TV ̂ plements are far cheaper Aan the d i^ s
Type II diabetes sufferers, he kaid, and insulin diabetes patients currently
produce insulin — a hormone that helps 
blood sugar control — but their bodies 
can’t use it. In type I diabetes, the body 
doesn’t produce insulin.
Both are serious health risks and can 
cause probleihs like heart disease or eye 
problems. Collier said.
Type n  diabetes is far more common, 
said CoUier, who’s also a registered di- 
etitian.The Canadian Diabetes Associa­
tion says 6,000 people in Thunder Bay 
suffer from diabetes, and about 90 per 
cent are type n. About 1.5 milUon people 
in Canada have a form of diabetes.
If CoUier’s research proves chromium
need.
CoUier is looking for volunteers with 
type n diabetes tp help with the study It 
wiU be placebo-cbntroUed: half the par­
ticipants wiU take chromium supple­
ment piUs; the others wiU take a placebo.
The first stage wUl last two months, 
foUowed by a two-month break..
Then the groups will switch, taking 
the opposite piU, for another two 
months.
Results wUl likely be known by sum­
mer, he said.
For more information or to volunteer, 
e-maU djcoUie@mail.lakeheadu.ca or 
-V    caU 807-766-5775.
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Dear Potential Participant,
My name is Denis Collier. I am a candidate for a Master's o f Science degree from Lakehead 
University, and a registered dietitian. I am the primary researcher in a study entitled “The Effect 
o f Chromium Supplementation on Blood Glucose Control in Individuals with Type 2 Diabetes”. 
Your participation in this study would be greatly appreciated.
There have been several reports in the scientific literature o f chromium's ability to improve blood 
glucose control. This finding would be particularly important to individuals with diabetes. 
However, not all studies have found this result. For this reason, more research is needed to 
determine if  taking chromium supplements can truly improve your blood glucose control.
Should you decide to participate, you will report for a routine blood sample sometime in early 
November. This would be to determine your level o f haemoglobin A le  (HbAlc) before the study 
starts. Immediately after this test you will begin taking a daily pill which will be either 400 pg o f  
GTF chromimn or a placebo (neither o f us will know which it really is). This will continue until 
early January at which time your HbAlc level will be tested again. The following two months 
will serve as a “washout” period -  essentially for these two months you will have a break from 
this study. The exact same process used in the November-January test period will be repeated 
from early March to early May, with the only difference being that this time you will receive the 
opposite pill. Should you desire, the results o f the study can be made available to you after it is 
completed.
By participating in this study, benefits may come to you personally and to other individuals with 
diabetes. You may find that chromium improves yoin blood glucose control. As well, the results 
of this study may ultimately go on to help many other people with the disease.
Participation in this study is unlikely to have any negative side effects. Toxic effects from 
chromium are exceptionally rare; only two cases have ever been reported and even these cases are 
considered to be questionable. Also, in these cases, a different form of chromium than the one 
that will be used in this study was ingested. Chromium has an established safety factor that is 
much higher than many other similar minerals. No controlled study using an orally administered 
chromium supplement has documented negative side effects o f any kind in the last 30 years.
Participation in the study is totally voluntary and you may withdraw at any time. Any information 
obtained about you will be kept confidential. A code number will be used instead o f your name to 
record and analyze the data which you supply. The data records will be stored under lock at 
Lakehead University for a period o f seven years.
Again, I hope you give strong consideration to participating in this worthwhile study.
Sincerely,
Denis Collier, RD, M.Sc. candidate Ian Newhouse, Ph.D.
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I ,_____________________________ have read and understood the cover letter of
the study entitled “The Effect of Chromium Supplementation on Blood Glucose Control 
in Individuals with Type 2 Diabetes”. Please consider this letter my formal consent to 
participate in the study.
I am aware that being involved in this study means participating in the following:
1) Taking a pill every day from early November to early January; and then again from 
early March to early May. In one of these two-month periods the pill will be a 400 pg 
GTF chromium supplement, the other time it will be a placebo; but I will not know which 
pill I am taking during either period.
2) Reporting for a routine blood sample four times (those times being early November, 
early January, early March and early May). The purpose of these blood tests will be to 
determine my level o f HbAlc.
I have been assured that the chances of developing any negative side effects from 
taking GTF chromium are very small. No controlled study using an orally administered 
chromium supplement has documented any negative side effects in the last 30 years.
I am aware that I may withdraw from this study at anytime.
Should I desire, I have been informed that I may have access to the results of the 
study once it is completed.
I have been informed that any information obtained about me will be kept 
confidential. A code number instead of my actual name will be used to record and 
analyze the data which I will provide.
I realize that by participating in this study, my own blood glucose control may 
improve. Also, the findings of this study may go on to help other people with diabetes.
If at any time during this study I should find that questions arise, Denis Collier,
the primary researcher has urged me not to hesitate to contact him using the contact
information provided.
Signature of Participant:___________________  Date:______________________
Witness: Date:
Primary Researcher:___________________________  Date:
Research Advisor: Date.
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